HealthWarehouse (HEWA) AI Stock Analysis

• Market Cap: $3.63M
• Dividend Yield: N/A
• Average Volume (3M): 1.13K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.57
• Revenue Growth: 22.18%
• EPS Growth: 11.25%
• Country: US
• Employees: 103
• Sector: Healthcare
• Sector Strength: 74
• Industry: Healthcare Providers & Services
• EPS (TTM): -0.03
• Shares Outstanding: 42,649,000
• 10 Day Avg. Volume: 1,003
• 30 Day Avg. Volume: 1,126
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.25
• Price to Cash Flow (P/CF): 33.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

HealthWarehouse's stock is currently facing challenges due to its financial instability and lack of profitability, reflected in the negative P/E ratio. Although there is strong revenue growth and improving cash flow, negative equity and bearish technical indicators weigh on the overall assessment. Valuation concerns are compounded by the lack of dividend yield, making the stock less appealing in the near term.

HealthWarehouse Business Overview & Revenue Model

Company Description

HealthWarehouse.com, Inc. is an online pharmacy, which engages in the sale and delivery of prescriptions focusing on the out-of-pocket prescription drug market. It offers prescription medications and over-the-counter products. The company was founded by Lalit P. Dhadphale in August 2007 and is headquartered in Florence, KY.

How the Company Makes Money

HealthWarehouse makes money through its e-commerce platform, where it sells prescription medications, over-the-counter drugs, and various health and wellness products directly to consumers. The company's primary revenue stream is generated from the sale of these pharmaceutical products. HealthWarehouse also benefits from its partnerships with insurance providers, which can help drive traffic and sales through reimbursement arrangements. Additionally, the company's cost-effective online distribution model allows it to maintain competitive pricing, which can attract a larger customer base and enhance sales growth.

HealthWarehouse Financial Statement Overview

Summary

HealthWarehouse shows strong revenue growth and improving cash flows but is challenged by negative profitability and financial instability due to high liabilities and negative equity. The mixed financial performance suggests potential for recovery if profitability and debt management improve.

Income Statement

HealthWarehouse shows a strong revenue growth trajectory, with a notable increase in revenue from $16.1M in 2021 to $24.8M TTM (Trailing-Twelve-Months). However, the company is facing challenges with profitability, as indicated by negative net profit margins and EBIT margins across the board. The gross profit margin remains healthy at around 51% for TTM, which suggests good control over cost of sales despite the negative net income.

Balance Sheet

The balance sheet reflects financial instability with significant negative stockholders' equity, indicating that liabilities exceed assets. The debt-to-equity ratio is undefined due to negative equity, which poses a risk. Additionally, the return on equity is not meaningful due to negative net income. Despite these challenges, the equity ratio has shown improvement in asset management.

Cash Flow

Cash flows from operating activities have turned positive in TTM, indicating an improving operational efficiency compared to previous years. Free cash flow is also positive, showing a significant recovery from prior periods. However, the ratios of operating and free cash flow to net income are skewed due to negative net income, emphasizing ongoing profitability issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
16.89M	20.28M	18.14M	16.14M	17.18M	15.76M
	Gross Profit
11.49M	12.17M	11.94M	11.13M	11.35M	10.36M
	EBIT
-556.54K	-1.62M	-784.08K	-359.62K	-49.12K	155.70K
	EBITDA
-421.97K	-1.28M	-559.33K	-224.76K	84.45K	319.36K
	Net Income Common Stockholders
-809.50K	-1.77M	-952.03K	-572.50K	441.78K	-99.40K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.82M	567.96K	1.04M	2.18M	1.82M	1.07M
	Total Assets
3.34M	3.21M	3.97M	3.62M	3.34M	2.51M
	Total Debt
2.14M	2.09M	2.39M	2.15M	2.14M	3.50M
	Net Debt
326.78K	1.52M	1.35M	-31.03K	326.78K	2.43M
	Total Liabilities
6.00M	7.21M	7.00M	6.41M	6.00M	6.11M
	Stockholders Equity
-2.66M	-4.01M	-3.03M	-2.79M	-2.66M	-3.61M
Cash Flow		Free Cash Flow
-597.79K	-473.81K	-1.14M	313.64K	240.79K	600.39K
	Operating Cash Flow
-392.71K	-163.84K	-624.45K	400.51K	250.87K	601.55K
	Investing Cash Flow
-205.08K	-309.97K	-512.85K	-86.86K	-10.08K	33.84K
	Financing Cash Flow
0.00	0.00	0.00	0.00	555.95K	4.85K

HealthWarehouse Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HEWA, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.70 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HEWA.

HealthWarehouse Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MCK	77 Outperform	$82.92B	30.32	51.23%	0.40%	14.29%	-1.20%
CVS	76 Outperform	$86.54B	18.77	6.07%	3.88%	4.02%	-43.51%
AMRX	62 Neutral	$2.79B	―	106.97%	―	16.73%	-22.44%
PETS	58 Neutral	$83.45M	397.20	0.36%	―	-10.82%	―
WBA	51 Neutral	$9.62B	―	-60.05%	8.99%	5.62%	-1637.59%
HEWA	50 Neutral	$3.63M	―	27.06%	―	22.18%	11.25%
Sector *	49 Neutral	$6.95B	0.65	-53.57%	2.47%	21.51%	0.74%